Mahamad Maifiah Mohd Hafidz, Zhu Yan, Tsuji Brian T, Creek Darren J, Velkov Tony, Li Jian
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
International Institute for Halal Research and Training, International Islamic University Malaysia, 50728, Kuala Lumpur, Malaysia.
J Biomed Sci. 2022 Oct 30;29(1):89. doi: 10.1186/s12929-022-00874-3.
Understanding the mechanism of antimicrobial action is critical for improving antibiotic therapy. For the first time, we integrated correlative metabolomics and transcriptomics of Pseudomonas aeruginosa to elucidate the mechanism of synergistic killing of polymyxin-rifampicin combination.
Liquid chromatography-mass spectrometry and RNA-seq analyses were conducted to identify the significant changes in the metabolome and transcriptome of P. aeruginosa PAO1 after exposure to polymyxin B (1 mg/L) and rifampicin (2 mg/L) alone, or in combination over 24 h. A genome-scale metabolic network was employed for integrative analysis.
In the first 4-h treatment, polymyxin B monotherapy induced significant lipid perturbations, predominantly to fatty acids and glycerophospholipids, indicating a substantial disorganization of the bacterial outer membrane. Expression of ParRS, a two-component regulatory system involved in polymyxin resistance, was increased by polymyxin B alone. Rifampicin alone caused marginal metabolic perturbations but significantly affected gene expression at 24 h. The combination decreased the gene expression of quorum sensing regulated virulence factors at 1 h (e.g. key genes involved in phenazine biosynthesis, secretion system and biofilm formation); and increased the expression of peptidoglycan biosynthesis genes at 4 h. Notably, the combination caused substantial accumulation of nucleotides and amino acids that last at least 4 h, indicating that bacterial cells were in a state of metabolic arrest.
This study underscores the substantial potential of integrative systems pharmacology to determine mechanisms of synergistic bacterial killing by antibiotic combinations, which will help optimize their use in patients.
了解抗菌作用机制对于改善抗生素治疗至关重要。我们首次整合了铜绿假单胞菌的相关代谢组学和转录组学,以阐明多粘菌素-利福平联合用药协同杀菌的机制。
采用液相色谱-质谱联用和RNA测序分析,以确定铜绿假单胞菌PAO1在单独暴露于多粘菌素B(1mg/L)和利福平(2mg/L)或联合用药24小时后的代谢组和转录组的显著变化。利用基因组规模的代谢网络进行综合分析。
在最初4小时的治疗中,多粘菌素B单药治疗引起了显著的脂质紊乱,主要影响脂肪酸和甘油磷脂,表明细菌外膜严重紊乱。单独使用多粘菌素B可增加参与多粘菌素抗性的双组分调节系统ParRS的表达。单独使用利福平引起的代谢紊乱较小,但在24小时时显著影响基因表达。联合用药在1小时时降低了群体感应调节的毒力因子的基因表达(例如参与吩嗪生物合成、分泌系统和生物膜形成的关键基因);并在4小时时增加了肽聚糖生物合成基因的表达。值得注意的是,联合用药导致核苷酸和氨基酸大量积累,持续至少4小时,表明细菌细胞处于代谢停滞状态。
本研究强调了整合系统药理学在确定抗生素联合用药协同杀菌机制方面的巨大潜力,这将有助于优化其在患者中的应用。